OBJECTIVES: Survival outcomes from a single-arm phase 2 blinatumomab study in patients with minimal residual disease (MRD)-positive B-cell precursor (BCP)-acute lymphoblastic leukaemia (ALL) were compared with those receiving standard of care (SOC) in a historic data set. METHODS: The primary analysis comprised adult Philadelphia chromosome (Ph)-negative patients in first complete haematologic remission (MRD ≥ 10-3 ). Relapse-free survival (RFS) and overall survival (OS) were compared between blinatumomab- and SOC-treatment groups. Baseline differences between groups were adjusted by propensity scores. RESULTS: The primary analysis included 73 and 182 patients from the blinatumomab and historic data sets, respectively. When weighted by age to the blinatumomab-treatment group, median RFS was 7.8 months and median OS was 25.9 months in the SOC-treated group. In the blinatumomab study, median RFS was 35.2 months; median OS was not evaluable. Propensity score weighting achieved balance with seven baseline prognostic factors. With adjustment for haematopoietic stem cell transplantation (HSCT) status, a 50% reduction in risk of relapse or death was observed with blinatumomab vs SOC. Median RFS, unadjusted for HSCT status, was 35.2 months with blinatumomab and 8.3 months with SOC. CONCLUSIONS: These analyses suggest that blinatumomab improves RFS, and possibly OS, in adults with MRD-positive Ph-negative BCP-ALL vs SOC.

'Sapienza' University of Rome Rome Italy

Biostatistics Amgen Inc Thousand Oaks CA USA

Center for Observational Research Amgen Inc Thousand Oaks CA USA

Centre for Observational Research Amgen Ltd Uxbridge UK

Clinical Development Amgen GmbH Munich Germany

Hôpital Saint Louis University Paris Diderot Paris France

ICO Hospital Germans Trias i Pujol Jose Carreras Research Institute Barcelona Spain

J W Goethe University Hospital Frankfurt Germany

Maria Sklodowska Curie Institute Oncology Center Gliwice Poland

National Research Center for Hematology Moscow Russia

Policlinico S Orsola Istituto Seragnoli Bologna Italy

University Hospital and CEITEC Masaryk University Brno Czech Republic

University Hospital Goethe University Frankfurt Germany

University Hospital Schleswig Holstein Kiel Germany

UOC Ematologia Ospedale dell'Angelo Mestre Venezia Italy

000      

00000naa a2200000 a 4500

001      

bmc20028307

003      

CZ-PrNML

005      

20240516084045.0

007      

ta

008      

210105s2020 xxk f 000 0|eng||

009      

AR

024    7_

$a 10.1111/ejh.13375 $2 doi

035    __

$a (PubMed)31876009

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Gökbuget, Nicola $u University Hospital, Goethe University, Frankfurt, Germany.

245    10

$a Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia / $c N. Gökbuget, H. Dombret, S. Giebel, M. Brüggemann, M. Doubek, R. Foa, D. Hoelzer, C. Kim, G. Martinelli, E. Parovichnikova, J. Maria Ribera, M. Schoonen, C. Tuglus, G. Zugmaier, R. Bassan,

520    9_

$a OBJECTIVES: Survival outcomes from a single-arm phase 2 blinatumomab study in patients with minimal residual disease (MRD)-positive B-cell precursor (BCP)-acute lymphoblastic leukaemia (ALL) were compared with those receiving standard of care (SOC) in a historic data set. METHODS: The primary analysis comprised adult Philadelphia chromosome (Ph)-negative patients in first complete haematologic remission (MRD ≥ 10-3 ). Relapse-free survival (RFS) and overall survival (OS) were compared between blinatumomab- and SOC-treatment groups. Baseline differences between groups were adjusted by propensity scores. RESULTS: The primary analysis included 73 and 182 patients from the blinatumomab and historic data sets, respectively. When weighted by age to the blinatumomab-treatment group, median RFS was 7.8 months and median OS was 25.9 months in the SOC-treated group. In the blinatumomab study, median RFS was 35.2 months; median OS was not evaluable. Propensity score weighting achieved balance with seven baseline prognostic factors. With adjustment for haematopoietic stem cell transplantation (HSCT) status, a 50% reduction in risk of relapse or death was observed with blinatumomab vs SOC. Median RFS, unadjusted for HSCT status, was 35.2 months with blinatumomab and 8.3 months with SOC. CONCLUSIONS: These analyses suggest that blinatumomab improves RFS, and possibly OS, in adults with MRD-positive Ph-negative BCP-ALL vs SOC.

650    _2

$a mladiství $7 D000293

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a protilátky bispecifické $x terapeutické užití $7 D018033

650    _2

$a antitumorózní látky $x terapeutické užití $7 D000970

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a reziduální nádor $7 D018365

650    _2

$a pre-B-buněčná leukemie $x farmakoterapie $x patologie $7 D015452

650    _2

$a recidiva $7 D012008

650    12

$a standardní péče $7 D059039

650    _2

$a analýza přežití $7 D016019

650    _2

$a mladý dospělý $7 D055815

655    _2

$a časopisecké články $7 D016428

700    1_

$a Dombret, Hervé $u Hôpital Saint-Louis, University Paris Diderot, Paris, France. $7 xx0316388

700    1_

$a Giebel, Sebastian $u Maria Sklodowska-Curie Institute-Oncology Center, Gliwice, Poland.

700    1_

$a Brüggemann, Monika $u University Hospital Schleswig-Holstein, Kiel, Germany.

700    1_

$a Doubek, Michael $u University Hospital and CEITEC Masaryk University, Brno, Czech Republic.

700    1_

$a Foa, Robin $u 'Sapienza' University of Rome, Rome, Italy. $7 xx0317383

700    1_

$a Hoelzer, Dieter $u J.W. Goethe University Hospital, Frankfurt, Germany.

700    1_

$a Kim, Christopher $u Center for Observational Research, Amgen Inc, Thousand Oaks, CA, USA.

700    1_

$a Martinelli, Giovanni $u Policlinico S Orsola Istituto Seragnoli, Bologna, Italy.

700    1_

$a Parovichnikova, Elena $u National Research Center for Hematology, Moscow, Russia.

700    1_

$a Maria Ribera, Josep $u ICO-Hospital Germans Trias i Pujol, Jose Carreras Research Institute, Barcelona, Spain.

700    1_

$a Schoonen, Marieke $u Centre for Observational Research, Amgen Ltd, Uxbridge, UK.

700    1_

$a Tuglus, Catherine $u Biostatistics, Amgen Inc, Thousand Oaks, CA, USA.

700    1_

$a Zugmaier, Gerhard $u Clinical Development, Amgen (Europe) GmbH, Munich, Germany.

700    1_

$a Bassan, Renato $u UOC Ematologia, Ospedale dell'Angelo, Mestre-Venezia, Italy. $7 xx0317382

773    0_

$w MED00001620 $t European journal of haematology $x 1600-0609 $g Roč. 104, č. 4 (2020), s. 299-309

856    41

$u https://pubmed.ncbi.nlm.nih.gov/31876009 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20210105 $b ABA008

991    __

$a 20240516084039 $b ABA008

999    __

$a ok $b bmc $g 1608642 $s 1119487

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2020 $b 104 $c 4 $d 299-309 $e 20200124 $i 1600-0609 $m European journal of haematology $n Eur J Haematol $x MED00001620

GRA    __

$p Amgen (Europe) GmBH

LZP    __

$a Pubmed-20210105